121 related articles for article (PubMed ID: 6384577)
1. Aclarubicin in the treatment of multiple myeloma.
Sezaki T; Adachi T; Ishii H; Asano K; Takahashi I; Kimura I
Jpn J Clin Oncol; 1984 Sep; 14(3):353-8. PubMed ID: 6384577
[TBL] [Abstract][Full Text] [Related]
2. [Clinical responses and side effects of aclarubicin (ACR) in the treatment of multiple myeloma].
Adachi T; Sezaki T; Ishii H; Hasegawa M; Asano K; Takahashi I; Kimura I
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1653-8. PubMed ID: 6347087
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Gockerman JP; Silberman H; Bartolucci AA
Cancer Treat Rep; 1987; 71(7-8):773-4. PubMed ID: 3300970
[No Abstract] [Full Text] [Related]
4. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of aclacinomycin A.
Van Echo DA; Whitacre MY; Aisner J; Applefeld MM; Wiernik PH
Cancer Treat Rep; 1982 May; 66(5):1127-32. PubMed ID: 6952961
[TBL] [Abstract][Full Text] [Related]
6. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
[TBL] [Abstract][Full Text] [Related]
8. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
9. Aclarubicin: experimental and clinical experience.
Röthig HJ; Kraemer HP; Sedlacek HH
Drugs Exp Clin Res; 1985; 11(2):123-5. PubMed ID: 3915280
[TBL] [Abstract][Full Text] [Related]
10. Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity.
Aabo K; Mortensen SA; Skovsgaard T; Gymoese E
Cancer Treat Rep; 1983 Mar; 67(3):281-2. PubMed ID: 6572564
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
12. Experimental and clinical studies on aclarubicin in the treatment of solid tumors.
Kumai K; Kubota T; Ishibiki K; Abe O
Biomed Pharmacother; 1984; 38(7):332-7. PubMed ID: 6596963
[TBL] [Abstract][Full Text] [Related]
13. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
14. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
Warrell RP; Arlin ZA; Kempin SJ; Young CW
Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
[TBL] [Abstract][Full Text] [Related]
15. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule.
Casper ES; Gralla RJ; Young CW
Cancer Res; 1981 Jun; 41(6):2417-20. PubMed ID: 6940656
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of aclacinomycin-A in head and neck cancer].
Tsukuda M
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2335-41. PubMed ID: 6594077
[TBL] [Abstract][Full Text] [Related]
18. [Combined chemotherapy with cisplatin and aclarubicin hydrochloride for metastatic brain tumors].
Tanaka T; Kobayashi T; Kida Y
No Shinkei Geka; 1988 Jan; 16(1):23-8. PubMed ID: 3163105
[TBL] [Abstract][Full Text] [Related]
19. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
